A National, Multicentric, Open-label Study of Induction Treatment With VELCADE and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2015
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms RENVEL
- Sponsors PETHEMA Foundation
- 19 Nov 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 27 Feb 2013 Planned End Date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 30 Jul 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.